Stockreport

Hemispherx Provides an Update to Stockholders Highlighting Cancer Focus and $10 Million Booked Since Start of Year Will Support Increased Production of Ampligen for Immuno-Oncology Clinica...

HEMISPHERX BIOPHARMA  (HEB) 
NASDAQ:AMEX Investor Relations: hemispherx.net/mobile/investor-relations.php
PDF ORLANDO, Fla., May 02, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB) would like to share a letter with its stockholders today, highlighting 2 [Read more]